InnoCan Pharma (HAM:IP40) Interest Expense: €-0.01 Mil (TTM As of Mar. 2026)


HAM:IP40 InnoCan Pharma Corp HAM:IP40
59 GF Score
Price €1.34
GF Value €9.22
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma Interest Expense?

InnoCan Pharma HAM:IP40 -5.32% 59 Interest Expense is €-0.01 Mil as of Mar. 2026. GuruFocus rates HAM:IP40 with a GF Score™ of 59/100 and a GF Value™ of €9.22 (Possible Value Trap). The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. InnoCan Pharma's interest expense for the three months ended in Mar. 2026 was € -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. InnoCan Pharma's Operating Income for the three months ended in Mar. 2026 was € -0.68 Mil. InnoCan Pharma's Interest Expense for the three months ended in Mar. 2026 was € -0.01 Mil. InnoCan Pharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InnoCan Pharma  (HAM:IP40) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InnoCan Pharma's Interest Expense for the three months ended in Mar. 2026 was €-0.01 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-0.68 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €0.84 Mil.

InnoCan Pharma's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

InnoCan Pharma did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

InnoCan Pharma Interest Expense Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma Interest Expense Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.01 -0.00 0.00 -0.01 -0.00

InnoCan Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.01 -0.00 -0.01
HAM:IP40
59GF Score
InnoCan Pharma Corp HAM:IP40
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCan Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.01 Mil mean?
InnoCan Pharma (HAM:IP40) has a Interest Expense of €-0.01 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on InnoCan Pharma and its competitors.
Is InnoCan Pharma's Interest Expense too high?
InnoCan Pharma's current Interest Expense is €-0.01 Mil. Overall, InnoCan Pharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Interest Expense compare to PG and CL?
InnoCan Pharma's Interest Expense of €-0.01 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Consumer Packaged Goods company?
A good Interest Expense depends on the Consumer Packaged Goods industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on InnoCan Pharma and its competitors. InnoCan Pharma's current Interest Expense is €-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.22, compared to a current price of €1.34 — trading 85.5% below its estimated fair value. The current Interest Expense is €-0.01 Mil. InnoCan Pharma's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Interest Expense is €-0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.34 is trading 85.5% below its estimated GF Value™ of €9.22. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for HAM:IP40:

  • Interest Expense: €-0.01 Mil
  • GF Value™: €9.22 vs. price of €1.34 (85.5% below fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Other Exchanges INNPF:USAINNO:Canada
Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
59GF Score

Get the complete analysis for HAM:IP40

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.34
Price
€9.22
GF Value